Data Composite

Drug Recalls

Recent drug recall reports from the FDA (US) and Health Canada, newest first. Each entry links to the full record -- product description, reason for recall, and severity classification -- refreshed daily.

Carolina Infusion, LLC

US Class II Ongoing · initiated 2026-09-10

Lack of Assurance of Sterility: Related to formulation using bacteriostic water; Related to processing equipment used in compounded product.

Carolina Infusion, LLC

US Class II Ongoing · initiated 2026-09-10

Lack of Assurance of Sterility: Related to formulation using bacteriostic water; Related to processing equipment used in compounded product.

Carolina Infusion, LLC

US Class II Ongoing · initiated 2026-09-10

Lack of Assurance of Sterility: Related to formulation using bacteriostic water; Related to processing equipment used in compounded product.

Amneal Pharmaceuticals, LLC

US Class II Ongoing · initiated 2026-09-08

Defective Container; packets were found to be either empty or partially full.

Par Health USA, LLC

US Class II Ongoing · initiated 2026-09-08

Crystallization

Pfizer

US Class II Ongoing · initiated 2026-09-04

Lack of Assurance of Sterility

OurPharma LLC

US Class II Ongoing · initiated 2026-09-03

Labeling: Not Elsewhere Classified: Complaint received on 08/31/2026 regarding the discrepancy of the IV bag expiry (07/31/2026 and 11/30/2026) and the product …

Inventia Healthcare Limited

US Class II Ongoing · initiated 2026-09-03

Failed Dissolution Specifications

SV Labs Toronto Corporation

US Class II Ongoing · initiated 2026-09-01

Microbial contamination of topical product.

SV Labs Toronto Corporation

US Class II Ongoing · initiated 2026-09-01

Microbial contamination of topical product.

JAMP Temozolomide

Canada Type II Ongoing · initiated 2026-08-31

Product quality. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product, or for any health conce…

Supernus Pharmaceuticals, Inc.

US Class III Ongoing · initiated 2026-08-31

Failed dissolution specifications.

SUN PHARMA /TARO

US Class II Ongoing · initiated 2026-08-31

Failed Content Uniformity Specifications. Out of Specification for Assay during analysis at the 24- month long term stability station, at (25¿C,60%RH).

TerSera Therapeutics LLC

US Class II Ongoing · initiated 2026-08-31

Temperature Abuse: Product sat in a non-temperature-controlled FedEx trailer at ambient outdoor conditions for 25.5 hours.

Amneal Pharmaceuticals of New York, LLC

US Class II Ongoing · initiated 2026-08-28

Defective Delivery System: Possibility of no medication in the prefilled pen.

Apo-Semaglutide

Canada Type II Ongoing · initiated 2026-08-27

Product quality. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product, or for any health conce…

Macleods Pharmaceuticals Limited

US Class III Ongoing · initiated 2026-08-27

Failed Impurities/Degradation Specifications:Organic and unspecified impurities above specification.

Semaglutide Injection

Canada Type II Ongoing · initiated 2026-08-26

Product quality. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product, or for any health conce…

Mylan Pharmaceuticals Inc

US Class II Ongoing · initiated 2026-08-26

Failed Dissolution Specifications

Twins Herbal Idakole and Twins Herbal Pelorie

Canada Type I Ongoing · initiated 2026-08-25

Undeclared substance. Discontinue use of the affected products. Consult your healthcare provider for any health concerns.Do not buy or use unauthorized health p…

Ajanta Pharma USA Inc

US Class III Ongoing · initiated 2026-08-25

Failed impurities/degradation specifications: (OOS) for Organic Impurities by HPLC (Impurity-A) during testing at the 18 months long term stability. Result: 1.1…

Hikma Pharmaceuticals USA INC.

US Class II Ongoing · initiated 2026-08-24

Failed Impurities/Degradation Specifications: OOS result obtained for a process impurity, dicyclohexylurea (DCU).

Teva Pharmaceuticals USA, Inc

US Class II Ongoing · initiated 2026-08-24

Presence of Foreign Tablets/Capsules

ImprimisRx NJ LLC

US Class III Ongoing · initiated 2026-08-24

Subpotent Drug

Lexia LLC

US Class II Ongoing · initiated 2026-08-21

CGMP Deviations: Potential contamination of raw material